Nextsource Materials Inc. (TSX:NEXT, OTCQB:NSRCF) has released the results of a feasibility study that demonstrate the favourability of proceeding with the next stage of expansion at the Molo graphite mine and production facility in Madagascar.
The plan is to boost steady-state production of 150,000 tonnes of graphite concentrate per year.
Liberum has reiterated its 'buy' rating on Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) stock after the group unveiled a maiden JORC 2012-compliant feldspar resource estimate at its Ewoyaa spodumene lithium project in Ghana.
The estimate stands at 15.7 million tonnes at a concentration of 40.2% feldspar.
hVIVO PLC’s respiratory syncytial virus (RSV) drug contract announced on Wednesday “should be taken well by the market”, reckon Cavendish analysts, despite shares already ripping 80% higher year to date
This full-service, end-to-end contract is forecast to bring in revenues of £16.8 million from 2023 to 2025, with the bulk expected in 2024.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) has welcomed the steps announced by the US National Highway Traffic Safety Administration (NHTSA) towards the compulsory introduction of impaired-driving prevention technology in new vehicles.
Driver Monitoring Systems (DMS) are specifically mentioned as a technological solution that will be considered as part of its formal rulemaking process.
Intellectual property commercialisation specialist Frontier IP Group PLC (AIM:FIPP)’s portfolio company The Vaccine Group (TVG) has formed an advisory board comprising high-ranking veterinary experts to support the scale-up of its innovative herpesvirus-based vaccine platform.
Forming the advisory board marks a crucial step for TVG as it progresses in developing a robust vaccine pipeline for use in livestock, pets and wildlife to tackle a range of viral and bacterial pathogens that cause severe economic harm and can also pose a threat to human health.
hVIVO PLC said it has won a £16.8 million contract to provide its human challenge trial services to test a respiratory syncytial virus (RSV) drug candidate for one of the five largest pharmaceutical companies in the world.
The company announced the contract in a statement that also noted that revenue and earnings (EBITDA) are both expected to be ahead of previous market expectations for the current calendar year.
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) said it has identified another potential anomaly from the latest drilling and geophysical results at Scallywag, adjacent to its Havieron development in Paterson, Western Australia..
Magnetic tests highlighted the conductor at depth within a syncline fold structure along the mineralised trend from Havieron.
Canadian life sciences company Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has announced that its successful C$4.91 million (£2.9 million) fundraising will be used to accelerate the commercialisation of its innovative nasal photodisinfection technology.
Ondine’s cutting-edge technology, which targets the prevention of healthcare-associated infections (HAIs), offers a promising alternative to topical antibiotics and is vital in the fight against antimicrobial resistance.